Recent Posts
- Illinois Attorney General Files Lawsuit Against HIV/AIDS Nonprofit
- California Gov. Arnold Schwarzenegger Signs Budget That Cuts $52M From HIV/AIDS Programs
- Efforts Underway In Namibia To Treat Pediatric HIV
- HIV/AIDS Education Project Targeting Pennsylvania Black Women Examined
- Also In Global Health News: Uganda Male Circumcision; Malaria Vaccine; Potential Global Fund Grant In Cambodia; PMTCT Of HIV In Botswana
Random Posts
- Donors To Reevaluate Support For Myanmar's Fight Against HIV/AIDS
- Washington Post Examines HIV/AIDS Rights, Responsibilities Questions
- New Electron Microscopy Images Reveal The Assembly Of HIV
- Editorial Discusses Needle Exchange Restrictions Included In House Bill
- Research On Leishmaniasis In Ethiopia Benefits From $5 Million Grant To Hebrew U.
- Report Examines HIV/AIDS, Other Issues In Tanzanian Prisons
- New York Times Examines Campaign That Promotes HIV Awareness, Prevention Through Media
- Drinks Industry Supplanting Government Role In Alcohol Policies In Sub-Saharan Africa
- Review Of Brazil's HIV/AIDS Treatment Programs Shows Importance Of Generic Drugs, Researchers Say
- Five-Day Congress On AIDS In Asia-Pacific Concludes
Prescription AIDS Drugs
Contact Us
Johnson & Johnson’s Research Reflecting New Washington Policies
June 09th, 2009
| Patient / Public: |  |
|
| Health Professional: | |
|
| Article Opinions: | php?associatednewsid=152880′ rel=’nofollow’>0 posts |
Health care supplier Johnson & Johnson will focus on new treatments and improved tests for cancer and other diseases for which company perceives unmet needs, like BusinessWeek reports.
Even as several major products have been waiting for Food and Drug Administration ’s approval, analysts say the company has been making strides in its own clinical trials, according to Business Week. “In keeping with the Obama administration’s priorities for health-care reform, research directors for several disease areas at J&J said their teams have been doing larger patient studies of experimental drugs that compare them to widely used treatments rather than placebos, a new trend called comparative effectiveness research. And J&J is doing more studies seeking “hard endpoints” — for example, how many heart attacks or strokes are prevented by a drug, rather than improvements in cholesterol or blood sugar.”
“Patients and payers increasingly demand such information,” BusinessWeek reports, and analysts add that providing it will allow J&J to corner an instant market for the products when new treatments do gain FDA approval (Johnson, 6/4).
This information was reprinted from kaiserhealthnews.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Health Policy Report, search the archives and sign up for email delivery at kaiserhealthnews.org.
© Henry J. Kaiser Family Foundation. All rights reserved.
Related posts:
- Magic Johnson To Black Religious Leaders: Join HIV/AIDS Awareness, Prevention Efforts Patient / Public: Health Professional: Article Opinions: 0 posts...
- Black Women In Washington, D.C., Have Higher Rate Of AIDS Than Other Women, Study Finds Patient / Public: Health Professional: Article Opinions: ...
- HIV/AIDS Research Efforts Of New York Scientist Featured Patient / Public: Health Professional: Article Opinions: Brook Community...
- Kennedy’s Contributions To HIV/AIDS, Gay Rights Policies Recalled News Category Menu HIV / AIDS >Categories A-B Abortion...
- Ghana’s Justice Minster Calls For Workplace HIV, TB Policies Ghana’s minister of justice and attorney general, Betty Mould-Iddrisu, recently...
Related posts brought to you by Yet Another Related Posts Plugin.
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment
You must be logged in to post a comment.